Abstract
The indirubin (2) derivative undergoes condensation with hydroxylamine hydrochloride, resulting in the formation of a novel indirubin derivative (3) that incorporates both the oxime group and the piperidine heterocycle. This compound is subsequently treated with hydrochloric acid in ethanol, leading to the formation of the hydrochloride salt (3.HCl), which exhibits excellent solubility in water. The chemical structures of compounds (3) and (3.HCl) were determined using 1D and 2D nuclear magnetic resonance (NMR) spectroscopy, as well as high-resolution mass spectrometry with electrospray ionization (ESI). To evaluate their potential as anticancer agents, in vitro assays were conducted using three human cancer cell lines (A549, Hep-G2, SW480) and one murine cancer cell line (B16F10). These compounds, along with indirubin (1) and Bortezomib (BTZ), were tested. The results revealed that compounds (3) and (3.HCl) demonstrated significant antitumor activity against all four cancer cell lines, with concentrations ranging from 0.37 ± 0.01 to 0.53 ± 0.06 μM. Importantly, their activity surpassed that of indirubin (1) and BTZ. Furthermore, an in vivo anticancer activity assay was performed on compound (3.HCl) using the B16F10 cell line. After 18 days, the tumor size in the group treated with compound (3.HCl) was approximately eight times smaller than that of the control group, and nearly three times smaller than the group treated with BTZ.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
1H NMR Properties of Piperidine Derivatives (1991) Studies in Organic Chemistry, 43, 34–87. https://doi.org/10.1016/B978-0-444-88348-3.50007-6
Adachi J, Mori Y, Matsui S, Takigami H, Fujino J, Kitagawa H, Miller CA 3rd, Kato T, Saeki K, Matsuda T (2001) Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem 276:31475–31478. https://doi.org/10.1074/jbc.C100238200
Bektas I, Karaman S, Diraz E, Celik M (2016) The role of natural indigo dye in alleviation of genotoxicity of sodium dithionite as a reducing agent. Cytotechnology 68:2245–2255. https://doi.org/10.1007/s10616-016-0018-7
Cuong NM, Thuy DTT, Ha NV, Tai BH (2007) Isolation of indirubin from the leaves of Strobilanthes cusia. J Sci Technol 45:195–199
Cuong NM, Tai BH, Hoan DH (2010a) Studies on the acetylation and NMR reassignment of indirubin derivatives. Nat Prod Res 24:99–105. https://doi.org/10.1080/14786410802300469
Cuong NM, Tai BH, Hoan DH, Huong TT, Kim YH, Hyun JH, Kang HK (2010b) Inhibitory effects of indirubin derivatives on the growth of HL-60 leukemia cells. Nat Prod Commun 5:103–106
Dan NT, Quang HD, Van Truong V, Huu Nghi D, Cuong NM, Cuong TD, Toan TQ, Bach LG, Anh NHT, Mai NT, Lan NT, Van Chinh L, Quan PM (2020) Design, synthesis, structure, in vitro cytotoxic activity evaluation and docking studies on target enzyme GSK-3beta of new indirubin-3’-oxime derivatives. Sci Rep 10:11429. https://doi.org/10.1038/s41598-020-68134-8
Efferth T, Li PC, Konkimalla VS, Kaina B (2007) From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13:353–361. https://doi.org/10.1016/j.molmed.2007.07.001
Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1:60–67. https://doi.org/10.1038/9035
Ju Z, Sun J, Liu Y (2019) Molecular structures and spectral properties of natural indigo and indirubin: experimental and DFT studies. Molecules. https://doi.org/10.3390/molecules24213831
Kim JK, Park GM (2012) Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-kappaB and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflamm Res 61:319–325. https://doi.org/10.1007/s00011-011-0413-7
Knockaert M, Greengard P, Meijer L (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23:417–425. https://doi.org/10.1016/s0165-6147(02)02071-0
Laurent M, Karima B, Alexios-Leandros S, Prokopios M, Jacint B, Judit R (2006b) New 3’-, 7-substituted indirubins and their applications. In: New 3’-, 7-substituted indirubins and their applications, WO
Le TMD, Jung BK, Li Y, Duong HTT, Nguyen TL, Hong JW, Yun CO, Lee DS (2019) Physically crosslinked injectable hydrogels for long-term delivery of oncolytic adenoviruses for cancer treatment. Biomater Sci 7:4195–4207. https://doi.org/10.1039/c9bm00992b
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276:251–260. https://doi.org/10.1074/jbc.M002466200
Lei Z, Lai L, Chengyue Z, Yang W, Jing W, Qizheng Y (2017) Synthesis of novel indirubin derivatives and their effects on the proliferation, cell cycle and apoptosis in acute myeloblastic leukemia HL-60 cells. Chin J Org Chem 37:1523–1529. https://doi.org/10.6023/cjoc201704018
Li Y, Le Duy TM, Nam Bui Q, Yang HY, Lee DS (2019) Tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods for combined chemo- and photothermal cancer therapy. Carbohydr Polym 226:115281. https://doi.org/10.1016/j.carbpol.2019.115281
Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10:1255–1266. https://doi.org/10.1016/j.chembiol.2003.11.010
Laurent M, Karima B, Alexios-Le-Andros S, Prokopios M, Jacint B, Judit R (2006a) 7-substituted indirubin-3′oximes and their applications. In 7-substituted indirubin-3′oximes and their applications. WO
Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R (2005) Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 102:5998–6003. https://doi.org/10.1073/pnas.0409467102
Nguyen DT, Truong GN, Van Vuong T, Van TN, Manh CN, Dao CT, Thuy TDT, Van CL, Khac VT (2019) Synthesis of new indirubin derivatives and their in vitro anticancer activity. Chem Pap 73:1083–1092. https://doi.org/10.1007/s11696-018-0659-4
Saito H, Tabata K, Hanada S, Kanda Y, Suzuki T, Miyairi S (2011) Synthesis of methoxy- and bromo-substituted indirubins and their activities on apoptosis induction in human neuroblastoma cells. Bioorg Med Chem Lett 21:5370–5373. https://doi.org/10.1016/j.bmcl.2011.07.011
Sano M, Ichimaru Y, Kurita M, Hayashi E, Homma T, Saito H, Masuda S, Nemoto N, Hemmi A, Suzuki T, Miyairi S, Hao H (2017) Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3’-oxime and 5-methoxyindirubin 3’-oxime in vitro and in vivo. Cancer Lett 397:72–82. https://doi.org/10.1016/j.canlet.2017.03.031
Song JH, Lee JE, Cho KM, Park SH, Kim HJ, Kim YC, Kim TS (2016) 5-diphenylacetamido-indirubin-3’-oxime as a novel mitochondria-targeting agent with anti-leukemic activities. Mol Carcinog 55:611–621. https://doi.org/10.1002/mc.22307
Stasiak N, Kukula-Koch W, Glowniak K (2014) Modern industrial and pharmacological applications of indigo dye and its derivatives–a review. Acta Pol Pharm 71:215–221
Tu Y (2016) Artemisinin-a gift from traditional chinese medicine to the world (nobel lecture). Angew Chem Int Ed Engl 55:10210–10226. https://doi.org/10.1002/anie.201601967
Xiao Z, Hao Y, Liu B, Qian L (2002) Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 43:1763–1768. https://doi.org/10.1080/1042819021000006295
Yan L, Lai F, Chen X, Xiao Z (2015a) Discovery of novel indirubin-3’-monoxime derivatives as potent inhibitors against CDK2 and CDK9. Bioorg Med Chem Lett 25:2447–2451. https://doi.org/10.1016/j.bmcl.2015.03.066
Yan L, Lai F, Chen X, Xiao Z (2015b) Discovery of novel indirubin-3′-monoxime derivatives as potent inhibitors against CDK2 and CDK9. Bioorg Med Chem Lett 25:2447–2451. https://doi.org/10.1016/j.bmcl.2015.03.066
Acknowledgements
We extend our sincere appreciation and gratitude to Vietnam Innovation Network in Korea (VINK) for facilitating and fostering the valuable connections that have enriched our research endeavors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No potential conflict of interest was reported by the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nguyen, T.D., Le, T.M.D. Development of a novel indirubin derivative with enhanced anticancer properties: synthesis, in Vitro, and in Vivo evaluation. Chem. Pap. 78, 2469–2478 (2024). https://doi.org/10.1007/s11696-023-03253-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-023-03253-w